Sumit Capital’s VanEck Biotech ETF BBH Stock Holding History

Sumit Capital’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-2,584	Closed	-$229K	–	110
2013 Q4	$229K	Buy	+2,584	New	+$216K	0.41%	126

Other funds holding BBH

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NCM

Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

LFM

Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

AHS

Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

Sumit Capital's BBH Position: Q1 2014 in Review

Sumit Capital sold out of VanEck Biotech ETF (BBH) in Q1 2014, closing a stake of 2,584 shares — an estimated $229K sold.

Sumit Capital first reported a position in BBH in Q4 2013 and held it in 1 quarter. The position peaked at $229K in Q4 2013. 59 funds tracked by Wall St. Rank hold BBH as of Q1 2014.

Sumit Capital reported no remaining VanEck Biotech ETF position as of Q1 2014 after selling out during the quarter.
Sumit Capital sold 2,584 VanEck Biotech ETF shares in Q1 2014, an estimated $229K.
Sumit Capital first reported a position in VanEck Biotech ETF in Q4 2013 and held it in 1 quarter.
Sumit Capital's VanEck Biotech ETF position peaked at $229K in Q4 2013.
59 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2014.

Based on Sumit Capital's 13F filing for Q1 2014, filed 7 May 2014.